Motley Rice reached a $43 million settlement with Medtronic, Inc. on behalf of shareholders who purchased the company’s common stock and suffered losses.
Motley Rice reached an anti-trust settlement to resolve litigation alleging drug manufacturers Boehringer Ingelheim and Teva Pharmaceutical engaged in an alleged pay-for-delay scheme to block generic competition for stroke medication Aggrenox®.
The National Law Journal announced finalists for its 2018 Elite Trial Lawyers and has named Motley Rice a finalist in four categories for its “exemplary performance in cutting edge work.”
The Connecticut Law Tribune has recognized Motley Rice consumer fraud attorney Mathew Jasinski as a “New Leader in Law” for 2018.